- Home
- ANIX vs ATYR Comparison
ANIX vs ATYR Comparison
Compare ANIX & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | ATYR |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | United States |
| Employees | N/A | 59 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 83.3M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANIX | ATYR |
|---|---|---|
| Price | $2.55 | $0.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 8 |
| Target Price | ★ $8.67 | $4.20 |
| AVG Volume (30 Days) | 88.7K | ★ 985.5K |
| Earning Date | 03-09-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.33 | $0.64 |
| 52 Week High | $5.46 | $7.29 |
Technical Indicators
Market Signals| Indicator | ANIX | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 34.14 | 37.34 |
| Support Level | N/A | $0.67 |
| Resistance Level | $3.10 | $0.85 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 13.49 | 1.23 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).